LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP decreased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 65.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 8,083 shares of the medical instruments supplier’s stock after selling 15,389 shares during the quarter. Bridgewater Associates LP’s holdings in LeMaitre Vascular were worth $751,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its stake in shares of LeMaitre Vascular by 14.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,643 shares of the medical instruments supplier’s stock worth $375,000 after buying an additional 695 shares in the last quarter. GAMMA Investing LLC raised its position in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in LeMaitre Vascular by 240.2% in the second quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock worth $929,000 after acquiring an additional 7,976 shares in the last quarter. Linden Thomas Advisory Services LLC boosted its position in shares of LeMaitre Vascular by 3.4% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 31,560 shares of the medical instruments supplier’s stock valued at $2,597,000 after purchasing an additional 1,034 shares in the last quarter. Finally, OLD National Bancorp IN bought a new position in shares of LeMaitre Vascular during the 2nd quarter valued at about $228,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $105.47 on Tuesday. LeMaitre Vascular, Inc. has a fifty-two week low of $52.55 and a fifty-two week high of $109.58. The stock’s 50-day moving average is $95.80 and its two-hundred day moving average is $88.23. The firm has a market cap of $2.37 billion, a P/E ratio of 57.63, a PEG ratio of 2.62 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.33 EPS. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is presently 34.97%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares of the company’s stock, valued at $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on LMAT. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities increased their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. Barrington Research lifted their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Finally, Oppenheimer reiterated an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.